SGP

Spyglass Pharma, Inc. Health Care Surgical & Medical Instruments & Apparatus Russell 3000

$32.24Close $71.0MMarket cap $17.56 – $32.8652-week range Nov 5, 2026Next report

Highlights

Cautions

Results soon Nov 5, 2026, in 4 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 6, 2026

Off 12-month high 2%

1wk 13.2% price change

1mo 24.0% price change

12-month return 22% total, dividends included

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B — price / book

Earnings yield — EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE — return on equity

Free cash margin — -$33.5M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 5.3% $1.71 a day · 2×ATR $28.82

RS — vs the universe

Trend — trend template

Relative volume 0.9× vs 50-day average

Up/down volume 0.94 50 sessions

Implied move — no option chain · report Nov 5, 2026

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Liabilities exceed assets Shareholders' equity is negative at -$98.8M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.

Last reported Aug 6, 2026

Results reaction Aug 6, 2026+6% vs market2 sessions after results

Financials

2 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$39.9M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$33.5M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 2.20m +0.3% since FY2024

	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Operating income	-$27.1M	-$41.4M
Net income	-$29.2M	-$39.9M
Earnings per share	-$16.31	-$17.98
Free cash flow	-$24.0M	-$33.5M
Cash	$16.3M	$96.4M
Shareholders' equity	-$60.5M	-$98.8M
Shares outstanding	2.20m	2.20m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 6, 2026	Quarterly ↗	Jun 30, 2026	37d
May 14, 2026	Quarterly ↗	Mar 31, 2026	44d
Mar 26, 2026	Annual ↗	Dec 31, 2025	85d

Current reports

Filed	Disclosed
Oct 19, 2026	Other events ↗
Oct 1, 2026	Regulation FD · Other events ↗
Aug 6, 2026	Results ↗
May 14, 2026	Results ↗
Mar 26, 2026	Results ↗
Mar 9, 2026	Other events ↗
Feb 13, 2026	Director or officer change ↗
Feb 9, 2026	Director or officer change · Charter or bylaws · Regulation FD ↗